01.10.2019 • News

CD&R Exits Univar

CD&R Exits Univar
CD&R Exits Univar

US private equity group Clayton, Dubilier & Rice (CD&R) has made a public offering of nearly 11.6 million shares (representing 6.9% of its issued and outstanding shares) in Univar Solutions.

CD&R said the offering represents the conclusion of a nine-year investment in Univar. Following the offering, which was expected to close on Sep. 25, 2019, CD&R will no longer hold any shares in the distributor.

Consequently, David Wasserman of CD&R will resign from Univar’s board of directors, where he has served since November 2010. Univar will not replace Wasserman, instead reducing the size of its board to 12 directors with effect from Oct. 31, 2019.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

From Catalogue to Collaboration

Enamine's Expert Insights Collection Is Free to Download
Enamine’s 35 Years of Advancing Drug Discovery

Enamine's Expert Insights Collection Is Free to Download

From catalogue to collaboration — explore 35 years of drug discovery breakthroughs, novel building blocks, and the science shaping tomorrow's medicines. Download your complimentary copy now.

most read